Segment Data (Tables)

12 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Financial Information for Company's Segments

(Millions of dollars)	2018			2017			2016
Revenues (a)
Medical (b)	$	8,616		$	7,419		$	7,965
Life Sciences	4,330			3,988			3,829
Interventional (b)	3,037			685			689
Total Revenues	$	15,983		$	12,093		$	12,483
Income Before Income Taxes
Medical (b) (c) (d)	$	2,624		$	1,907		$	1,807
Life Sciences (e)	1,207			772			793
Interventional (b) (c)	306			248			245
Total Segment Operating Income	4,137			2,927			2,845
Acquisitions and other restructurings	(744		)	(354		)	(728		)
Net interest expense	(641		)	(445		)	(367		)
Other unallocated items (f)	(1,578		)	(1,152		)	(676		)
Total Income Before Income Taxes	$	1,173		$	976		$	1,074
Assets
Medical (b)	$	23,493		$	15,552		$	16,370
Life Sciences	4,225			4,056			3,848
Interventional (b)	23,219			2,780			2,784
Total Segment Assets	50,938			22,388			23,002
Corporate and All Other (g)	2,966			15,347			2,584
Total Assets	$	53,904		$	37,734		$	25,586
Capital Expenditures
Medical (b)	$	560		$	486		$	464
Life Sciences	255			212			200
Interventional (b)	65			16			18
Corporate and All Other	14			13			12
Total Capital Expenditures	$	895		$	727		$	693
Depreciation and Amortization
Medical (b)	$	1,028		$	773		$	801
Life Sciences	275			254			254
Interventional (b)	658			52			56
Corporate and All Other	17			10			3
Total Depreciation and Amortization	$	1,978		$	1,088		$	1,114

(a)The Company has no material intersegment revenues.

(b)Prior-year amounts have been reclassified to reflect the movement of certain product offerings previously reported in the Medical segment and which are now reported in the Interventional segment, as further discussed above. Accordingly, all amounts presented in 2017 and 2016 for the Interventional segment are associated with these products.

(c)The amounts in 2018 included expense related to the recognition of a $478 million fair value step-up adjustment related to Bard's inventory on the acquisition date. The step-up adjustments recognized by the Medical and Interventional segments in 2018 were $60 million and $418 million, respectively.

(d)The amount in 2018 included $58 million of charges to write down the value of fixed assets primarily in the Diabetes Care unit.

(e)The amount in 2018 included $81 million of charges recorded to write down the carrying value of certain intangible and other assets in the Biosciences unit.

(f)The amounts in 2018, 2017 and 2016 comprised of foreign exchange, corporate expenses, and share-based compensation expense. Results in 2018 were impacted by the Company's change in its management reporting approach, as further discussed above. Results in 2017 included a $748 million non-cash charge resulting from a modification to the Company's dispensing equipment lease contracts with customers, as well as the reversal of certain litigation reserves as further discussed in Note 5. 

(g)Includes cash and investments and corporate assets.

Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment

Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.

(Millions of dollars)	2018		2017		2016
Revenues
United States	$	8,768	$	6,504	$	6,893
Europe	3,298		2,588		2,674
Greater Asia	2,460		1,744		1,692
Other	1,457		1,257		1,225
	$	15,983	$	12,093	$	12,483
Long-Lived Assets
United States	$	38,982	$	13,151	$	14,075
Europe	5,640		4,421		3,747
Greater Asia	851		578		586
Other	645		584		483
Corporate	375		366		329
	$	46,494	$	19,101	$	19,220